Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aurinia Pharm Ord (AUPH)

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 693,497
  • Shares Outstanding, K 142,110
  • Annual Sales, $ 45,610 K
  • Annual Income, $ -180,970 K
  • 60-Month Beta 0.92
  • Price/Sales 15.21
  • Price/Cash Flow N/A
  • Price/Book 1.64
Trade AUPH with:

Options Overview Details

View History
  • Implied Volatility 91.48% ( +3.35%)
  • Historical Volatility 132.39%
  • IV Percentile 20%
  • IV Rank 18.92%
  • IV High 167.23% on 12/03/21
  • IV Low 73.80% on 09/21/22
  • Put/Call Vol Ratio 0.13
  • Today's Volume 1,672
  • Volume Avg (30-Day) 3,154
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 126,297
  • Open Int (30-Day) 128,151

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.20
  • Number of Estimates 4
  • High Estimate -0.01
  • Low Estimate -0.28
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.49 +8.69%
on 11/22/22
8.40 -41.90%
on 10/31/22
-3.14 (-39.15%)
since 10/28/22
3-Month
4.49 +8.69%
on 11/22/22
8.52 -42.72%
on 10/28/22
-2.84 (-36.79%)
since 08/26/22
52-Week
4.49 +8.69%
on 11/22/22
24.45 -80.04%
on 12/28/21
-14.45 (-74.75%)
since 11/26/21

Most Recent Stories

More News
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of 66.67% and 46.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AUPH : 4.88 (unch)
HARP : 0.6899 (+0.42%)
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three months ended September 30, 2022. Amounts, unless specified otherwise, are expressed...

AUPH : 4.88 (unch)
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third quarter 2022 on Thursday, November 3, 2022, before...

AUPH : 4.88 (unch)
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today announced that...

AUPH : 4.88 (unch)
Aurinia (AUPH) Moves 13.1% Higher: Will This Strength Last?

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the...

AUPH : 4.88 (unch)
CALT : 17.85 (+3.72%)
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that the Company’s...

AUPH : 4.88 (unch)
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today announced that...

AUPH : 4.88 (unch)
Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval

Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.

AERI : 15.25 (+0.07%)
AUPH : 4.88 (unch)
SLNO : 1.0400 (-3.70%)
ACER : 1.1684 (-1.96%)
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced that the...

AUPH : 4.88 (unch)
Why Aurinia Pharmaceuticals Stock Briefly Spiked Today

Investors embraced the biotech's second-quarter results.

AUPH : 4.88 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

3rd Resistance Point 5.23
2nd Resistance Point 5.13
1st Resistance Point 5.01
Last Price 4.88
1st Support Level 4.78
2nd Support Level 4.68
3rd Support Level 4.55

See More

52-Week High 24.45
Fibonacci 61.8% 16.83
Fibonacci 50% 14.47
Fibonacci 38.2% 12.11
Last Price 4.88
52-Week Low 4.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar